Editorial Comment Adjuvant Antiplatelet Strategies in Coronary Thrombolysis
Richard C. Becker, MD, and Joel M. Gore, MD M ounting experimental and clinical evidence, coupled with a growing understanding of coronary arterial thrombogenesis, supports the hypothesis that the benefits of thrombolytic therapy in acute myocardial infarction depend primarily on achieving rapid recanalization and maintaining patency of the infarct-related vessel.
To achieve these goals it presently appears that, in addition to administration of effective thrombolytic agents, the implementation of adjunctive pharmacological strategies designed to inhibit either platelet activity or thrombin generation will be required. Although there are a number of potential mechanisms by which platelets may be inhibited, Yasuda et all describe in this issue of Circulation a unique antiplatelet agent, kistrin, which blocks the platelet GPIIb/IIIa receptor.
Coronary artery thrombi consist of both plateletrich and erythrocyte-rich zones, with the former predominating in most instances. A platelet-rich zone exists at the site of atherosclerotic plaque rupture, and erythrocyte-rich zones develop both proximal and distal to the area of vascular injury.
See p 1038 Examination of coronary artery thrombi with standard light microscopy, conventional staining techniques, and electron microscopy typically reveals a network of platelets immersed in fibrin. Platelet masses and columns consisting of tightly packed aggregates with varying degrees of swelling, degranulation, and pseudopod extension are also evident.2 In addition to being directly involved in thrombus formation, aggregating platelets can trigger intense vasoconstriction following the activation and release of two potent vasoactive mediatorsthromboxane A2 and serotonin.3
It is widely believed that heightened platelet activity is responsible for both thrombolytic resistance and coronary reocclusion, occurring in 20-25% and 10-15%, respectively, of acute myocardial infarction patients. Indeed, preformed whole blood or plasma clots are readily lysed with low concentrations of tissue-type plasminogen activator (t-PA), whereas platelet aggregates formed in platelet-rich plasma require a much higher concentration of t-PA for disaggregation.4 Similarly, erythrocyte-rich coronary arterial thrombi are consisten-tly lysed after an intravenous infusion of t-PA at low doses. In contrast, platelet-rich thrombi are relatively resistant to lysis even when extremely high doses of t-PA are administered.56 Of further clinical importance, high concentrations of circulating plasmin such as those achieved after administration of recombinant t-PA or streptokinase have been shown to increase platelet activation.7,8 Moreover, activated platelets release plasminogen activator inhibitor, a2antiplasmin, and other proteins that inhibit fibrinolysis from cytoplasmic granules; they also provide factor XIIIa for fibrin cross-linking.
The mechanisms responsible for platelet adhesion and platelet aggregation differ. Platelet adhesion is mediated by fibronectin, collagen, von Willebrand factor, and three specific platelet surface glycoproteins -GPIb, GPIc/IIa, and GPIa/IIa. In contrast, platelet aggregation is mediated by fibronectin, von Willebrand factor, vitronectin, and GPIIb/IIIa. The GPIIb/IIIa receptor is present at high density on the platelet surface with approximately 50,000 binding sites per cell. A number of platelet agonists, including thrombin, ADP, epinephrine, thromboxane A2, and collagen promote aggregation through a GPIIb/ Illa-fibrinogen-mediated interaction. Because the interaction of fibrinogen with its specific receptor found on the platelet-GPIIb/IIIa complex represents the final common pathway for platelet aggregation, a number of molecules that inhibit this interaction by blocking putative platelet binding sites on the fibrinogen molecule have been investigated. A group of synthetic peptides with the amino-terminal amino acid sequence Arg-Gly-Asp (RGD), including RGDS (RGD-Ser),9 RGDF (RGD-Phe),'0 and tyrosol pentadecapeptide of the carboxy-terminal portion of the gamma chain of fibrinogen," inhibit platelet aggregation in concentrations of 10 to 200 ,uM. More recently, four RGD-containing cysteine-rich peptides (Trigramin, Echistatin, Bitistatin, and Kistrin) were isolated from Trimeresurus gramineus, Echis carinatus, Bitis arietans, and Agkistrodon rhodostroma snake venoms, respectively.12-15 On a molar basis, these peptides are approximately 500-2,000 times more potent than RGDS peptides in blocking GPI1b/IIafibrinogen interactions and inhibiting fibrinogen-dependent platelet aggregation. The molecule investigated by Yasuda et all is an Mr 7,334 polypeptide composed of 68 amino acids containing the typical RGD recognition sequence.5
The canine model of coronary artery thrombosis with superimposed high-grade stenosis employed by Yasuda et al' typically yields a whole-blood clot rather than a platelet-rich clot. Therefore, thrombolytic resistance may be less profound, as evidenced by the 80% recanalization rate in the control animals receiving intravenous heparin and rt-PA. Furthermore, the substrate for reocclusion in this model is a whole-blood clot enriched with platelets during the transient reestablishment of coronary blood flow. Despite these methodological limitations, the investigators were able to show that the combination of rt-PA and kistrin increased the rate and extent of thrombolysis and prevented coronary reocclusion. Moreover, the effective dose was associated with only a transient prolongation of the bleeding time and inhibition of ADP and collagen-induced platelet aggregation. These findings are in contrast to those obtained in an earlier study by in which an effective dose of a GPI1b/IIIa monoclonal antibody (7E3 -F[Ab '12) completely abolished platelet aggregation and markedly prolonged the template bleeding time for the duration of the experiment. Although it is unknown to what extent these results can be extrapolated to humans in predicting hemorrhagic risk, it is currently hypothesized that complete and prolonged platelet inhibition may cause an unfavorable impairment of the hemostatic mechanism. Most clinicians and scientists engaged in the study of thrombolysis realize, however, that adjuvant strategies combining potent fibrinolytic, antiplatelet, and antithrombin agents may be associated with some increased risk of bleeding.
The importance of platelet activity in arterial thrombogenesis and overall thrombolytic efficacy is by no means newly recognized. Like Yasuda et al,' previous investigators have found other antiplatelet agents to be attractive thrombolytic agent adjuncts in animal thrombosis models (e.g., serotonin receptor antagonists,17 thromboxane A, receptor antagonists,17 combined serotonin and thromboxane A2 receptor antagonists,18 thromboxane synthetase inhibitors, 1920 prostacyclin analogues,21 and prostaglandin E122), as are specific antithrombins that inhibit platelet aggregation such as hirudin,23 argatroban,24 and D-phenylalanyl-L-prolyl-L-arginylchloromethyl ketone. 25 Despite the fact that the GPIIb/ Illa receptor may indeed be the preferred target for therapeutic intervention in thromboembolic disease,' the safety and efficacy of this class of antiplatelet agents will be proven or disproven by the results of carefully designed clinical studies in humans.
